Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
Φόρτωση...
Ημερομηνία
Συγγραφείς
Pectasides, D.
Fountzilas, G.
Aravantinos, G.
Kalofonos, H. P.
Efstathiou, E.
Salamalekis, E.
Farmakis, D.
Skarlos, D.
Briasoulis, E.
Economopoulos, T.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Gynecol Oncol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: Mucinous epithelial ovarian cancer (mEOC) representing about 10% of all EOC are known to be possibly resistant to platinum-based chemotherapy and bear a poorer prognosis with respect to other subtypes of EOC. This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC). METHODS: A retrospective analysis was performed in 47 patients with advanced stage of mEOC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 6/7/1983 and 25/2/2003. The outcome was compared to that of 94 patients with sEOC treated with the same protocols during the same study period (ratio mucinous: serous 1:2). RESULTS: One hundred forty-one patients (47 stages III and IV mEOC, 94 stages III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for mEOC was 38.5% (complete remission 18%) (95% CI 23.4-55.4%) and 70% (complete remission 47%) (95% CI 58.5-80.3%) for sEOC (P = 0.001). After a median follow-up of 77.8 months, median survival and time to tumor progression (TTP) were not significantly different between the two groups (33.2 months [95% CI 23.3-43.1 months] vs. 38.0 months [95% CI 26.8-49.2 months], P = 0.46, 11.8 months [95% CI 7.2-16.4 months] vs. 20.0 months [95% CI 15.7-24.2 months], P = 0.18, respectively). CONCLUSION: Patients with mEOC have significantly lower response to first-line platinum-based chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in inferior TTP or survival. Our data indicate that a new strategy for chemotherapy in mEOC should be adopted, one that focuses on new agents without cross-resistance to platinum agents.
Περιγραφή
Λέξεις-κλειδιά
Adenocarcinoma, Mucinous/*drug therapy/pathology/surgery, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Carboplatin/administration & dosage/*therapeutic use, Cisplatin/administration & dosage/*therapeutic use, Combined Modality Therapy, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms/*drug therapy/pathology/surgery, Paclitaxel/administration & dosage, Retrospective Studies, Survival Rate, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15863142
http://ac.els-cdn.com/S009082580500017X/1-s2.0-S009082580500017X-main.pdf?_tid=ab671e543367e45f7122b017e1d8e236&acdnat=1333703539_fe6d358290794b86caec87e681213b26
http://ac.els-cdn.com/S009082580500017X/1-s2.0-S009082580500017X-main.pdf?_tid=ab671e543367e45f7122b017e1d8e236&acdnat=1333703539_fe6d358290794b86caec87e681213b26
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής